Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 6/2009

01.06.2009 | Original Article

The immunosuppressive tumor microenvironment in hepatocellular carcinoma

verfasst von: Yan-Li Pang, Hua-Gang Zhang, Ji-Run Peng, Xue-Wen Pang, Shu Yu, Qiao Xing, Xin Yu, Lei Gong, Yan-Hui Yin, Yu Zhang, Wei-Feng Chen

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidence indicates the immunosuppressive nature of the local environment in tumor. The present study was focused on analyzing the immune status within hepatocellular carcinoma. In contrast to the increasing number of CD4+ T cells, CD8+, CD3CD56+, CD3+CD56+, and γδT cells were all found to be under-represented in tumor infiltrating lymphocytes. Notably, the relative abundance of CD3+CD56+ cells appeared to be correlated with patient survival. Functional analysis demonstrated that CD4+ cells in the tumor tended to produce more IL-10 but less IFN-γ, whereas CD8+ cells showed impaired capacity for the production of both IFN-γ and perforin. Consistent with previous reports, we observed a significant increase of Foxp3+ cells in the tumor tissue. Intriguingly, although over 90% of CD4+CD25high cells were found to be Foxp3+, the majority of Foxp3+ cells were identified in the CD4+CD25medium and CD4+CD25 subsets. In support of its role as a negative regulator, CD4+CD25high cells suppressed the proliferation of CD4+CD25 cells isolated from the same tissues in an APC dependent manner. In conclusion, the tumor microenvironment of hepatocellular carcinoma is featured by the presence of multiple immunosuppressive factors.
Literatur
1.
Zurück zum Zitat Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Buchler MW (1999) Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg 177:209–215PubMedCrossRef Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Buchler MW (1999) Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg 177:209–215PubMedCrossRef
2.
Zurück zum Zitat Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54:369–377PubMedCrossRef Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54:369–377PubMedCrossRef
3.
Zurück zum Zitat Bedossa P, Peltier E, Terris B, Franco D, Poynard T (1995) Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21:760–766PubMed Bedossa P, Peltier E, Terris B, Franco D, Poynard T (1995) Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21:760–766PubMed
5.
Zurück zum Zitat Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE (2005) Naturally acquired MAGE-A10- and SSX-2-specific CD8+T cell responses in patients with hepatocellular carcinoma. J Immunol 174:1709–1716PubMed Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE (2005) Naturally acquired MAGE-A10- and SSX-2-specific CD8+T cell responses in patients with hepatocellular carcinoma. J Immunol 174:1709–1716PubMed
6.
Zurück zum Zitat Chattopadhyay S, Chakraborty NG, Mukherji B (2005) Regulatory T cells and tumor immunity. Cancer Immunol Immunother 54:1153–1161PubMedCrossRef Chattopadhyay S, Chakraborty NG, Mukherji B (2005) Regulatory T cells and tumor immunity. Cancer Immunol Immunother 54:1153–1161PubMedCrossRef
7.
Zurück zum Zitat Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRef Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+CD25 naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRef
8.
Zurück zum Zitat Conroy H, Marshall NA, Mills KH (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27:168–180PubMedCrossRef Conroy H, Marshall NA, Mills KH (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27:168–180PubMedCrossRef
9.
Zurück zum Zitat Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef
10.
Zurück zum Zitat Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623–3633PubMedCrossRef Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623–3633PubMedCrossRef
11.
Zurück zum Zitat Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, O’Farrelly C (1999) The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163:2314–2321PubMed Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, O’Farrelly C (1999) The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163:2314–2321PubMed
12.
Zurück zum Zitat Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630–641PubMedCrossRef Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630–641PubMedCrossRef
13.
Zurück zum Zitat Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336PubMedCrossRef Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336PubMedCrossRef
14.
Zurück zum Zitat Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132:2328–2339PubMedCrossRef Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132:2328–2339PubMedCrossRef
15.
Zurück zum Zitat Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586–2593PubMedCrossRef Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586–2593PubMedCrossRef
17.
18.
Zurück zum Zitat Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRef Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRef
19.
Zurück zum Zitat Hwu P, Freedman RS (2002) The immunotherapy of patients with ovarian cancer. J Immunother 25:189–201PubMedCrossRef Hwu P, Freedman RS (2002) The immunotherapy of patients with ovarian cancer. J Immunother 25:189–201PubMedCrossRef
20.
Zurück zum Zitat Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:896–904PubMed Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:896–904PubMed
21.
Zurück zum Zitat Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H (1992) Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 22:256–263PubMed Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H (1992) Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 22:256–263PubMed
22.
Zurück zum Zitat Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337–342PubMedCrossRef Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337–342PubMedCrossRef
23.
Zurück zum Zitat Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005PubMedCrossRef Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005PubMedCrossRef
24.
Zurück zum Zitat Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902–911PubMedCrossRef Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902–911PubMedCrossRef
25.
Zurück zum Zitat Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341PubMedCrossRef Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341PubMedCrossRef
26.
Zurück zum Zitat Linehan DC, Goedegebuure PS (2005) CD25+CD4+ regulatory T-cells in cancer. Immunol Res 32:155–168PubMedCrossRef Linehan DC, Goedegebuure PS (2005) CD25+CD4+ regulatory T-cells in cancer. Immunol Res 32:155–168PubMedCrossRef
27.
Zurück zum Zitat Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4+CD25− T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883–2892PubMed Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4+CD25 T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883–2892PubMed
28.
Zurück zum Zitat Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH (2006) Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177:712–721PubMed Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH (2006) Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177:712–721PubMed
29.
30.
Zurück zum Zitat Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, Enk AH (2007) Depletion of CD4+CD25+human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723–2733PubMedCrossRef Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, Enk AH (2007) Depletion of CD4+CD25+human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723–2733PubMedCrossRef
31.
Zurück zum Zitat Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R (2000) Strategies for immunotherapy of cancer. Adv Immunol 75:235–282PubMedCrossRef Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R (2000) Strategies for immunotherapy of cancer. Adv Immunol 75:235–282PubMedCrossRef
32.
Zurück zum Zitat Mills KH (2004) Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4:841–855PubMedCrossRef Mills KH (2004) Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4:841–855PubMedCrossRef
33.
Zurück zum Zitat O’Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235–2246PubMedCrossRef O’Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235–2246PubMedCrossRef
34.
Zurück zum Zitat Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099PubMedCrossRef Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099PubMedCrossRef
35.
Zurück zum Zitat Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920PubMedCrossRef Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920PubMedCrossRef
36.
Zurück zum Zitat Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147PubMedCrossRef Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147PubMedCrossRef
37.
Zurück zum Zitat Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF (2004) The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 10:6946–6955PubMedCrossRef Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF (2004) The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 10:6946–6955PubMedCrossRef
38.
Zurück zum Zitat Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y (1994) Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73:2275–2279PubMedCrossRef Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y (1994) Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73:2275–2279PubMedCrossRef
39.
Zurück zum Zitat Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41:722–730PubMedCrossRef Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41:722–730PubMedCrossRef
40.
Zurück zum Zitat Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M (1998) Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27:407–414PubMedCrossRef Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M (1998) Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27:407–414PubMedCrossRef
41.
Zurück zum Zitat Wan YY, Flavell RA (2005) Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 102:5126–5131PubMedCrossRef Wan YY, Flavell RA (2005) Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 102:5126–5131PubMedCrossRef
42.
Zurück zum Zitat Wang RF (2006a) Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 16:106–114PubMedCrossRef Wang RF (2006a) Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 16:106–114PubMedCrossRef
43.
Zurück zum Zitat Wang RF (2006b) Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol 16:73–79PubMedCrossRef Wang RF (2006b) Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol 16:73–79PubMedCrossRef
44.
Zurück zum Zitat Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612PubMed Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612PubMed
45.
Zurück zum Zitat Wolf D, Rumpold H, Koppelstatter C, Gastl GA, Steurer M, Mayer G, Gunsilius E, Tilg H, Wolf AM (2006) Telomere length of in vivo expanded CD4+CD25+ regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother 55:1198–1208PubMedCrossRef Wolf D, Rumpold H, Koppelstatter C, Gastl GA, Steurer M, Mayer G, Gunsilius E, Tilg H, Wolf AM (2006) Telomere length of in vivo expanded CD4+CD25+ regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother 55:1198–1208PubMedCrossRef
46.
Zurück zum Zitat Xing Q, Pang XW, Peng JR, Yin YH, Li Y, Yu X, Zhou SP, Zhang Y, Chen WF (2008) Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem Biophys Res Commun 372:331–335PubMedCrossRef Xing Q, Pang XW, Peng JR, Yin YH, Li Y, Yu X, Zhou SP, Zhang Y, Chen WF (2008) Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem Biophys Res Commun 372:331–335PubMedCrossRef
47.
Zurück zum Zitat Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y (2006) Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45:254–262PubMedCrossRef Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y (2006) Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45:254–262PubMedCrossRef
48.
Zurück zum Zitat Yee C, Greenberg P (2002) Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2:409–419PubMedCrossRef Yee C, Greenberg P (2002) Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2:409–419PubMedCrossRef
49.
Zurück zum Zitat Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli GC, Ferrari C, Missale G (2004) Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. J Hepatol 40:102–109PubMedCrossRef Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli GC, Ferrari C, Missale G (2004) Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. J Hepatol 40:102–109PubMedCrossRef
50.
Zurück zum Zitat Zhang HG, Chen HS, Peng JR, Shang XY, Zhang J, Xing Q, Pang XW, Qin LL, Fei R, Mei MH, Leng XS, Chen WF (2007) Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother 56:1945–1954PubMedCrossRef Zhang HG, Chen HS, Peng JR, Shang XY, Zhang J, Xing Q, Pang XW, Qin LL, Fei R, Mei MH, Leng XS, Chen WF (2007) Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother 56:1945–1954PubMedCrossRef
51.
Zurück zum Zitat Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727PubMedCrossRef Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727PubMedCrossRef
52.
Zurück zum Zitat Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274PubMedCrossRef Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274PubMedCrossRef
Metadaten
Titel
The immunosuppressive tumor microenvironment in hepatocellular carcinoma
verfasst von
Yan-Li Pang
Hua-Gang Zhang
Ji-Run Peng
Xue-Wen Pang
Shu Yu
Qiao Xing
Xin Yu
Lei Gong
Yan-Hui Yin
Yu Zhang
Wei-Feng Chen
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0603-5

Weitere Artikel der Ausgabe 6/2009

Cancer Immunology, Immunotherapy 6/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.